2020
The Role of Medical Therapy for Menigniomas
Roque A, Omuro A. The Role of Medical Therapy for Menigniomas. 2020, 201-215. DOI: 10.1007/978-3-030-59558-6_13.Peer-Reviewed Original ResearchSystemic therapyProspective single-arm studyNatural historyCurrent NCCN guidelinesLower relapse rateMajority of patientsSingle-arm studySmall patient populationVaried outcome measuresNCCN guidelinesRefractory meningiomasRepeat surgerySurgical resectionSystemic treatmentLocal therapyMedical therapyProlong survivalRelapse rateSurgical optionsArm studyPatient populationSomatostatin analoguesGrade IGrade IIAntiangiogenic agents
2015
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology 2015, 18: 557-564. PMID: 26449250, PMCID: PMC4799682, DOI: 10.1093/neuonc/nov245.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAminopyridinesBiomarkers, TumorBlood-Brain BarrierBrain NeoplasmsCohort StudiesFemaleFollow-Up StudiesGlioblastomaHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPyrrolesReceptors, Granulocyte-Macrophage Colony-Stimulating FactorTissue DistributionTumor BurdenConceptsPhase II studyII studyRecurrent glioblastomaTumor tissueMedian drug levelsPrimary efficacy endpointProgression-free survivalBlood-brain barrierPretreatment baseline valuesBlood-tumor barrierExploratory endpointsInhibitor PLX3397Efficacy endpointPrimary endpointSecondary endpointsObjective responseSurgical resectionOral dosePharmacodynamic changesPharmacodynamic measuresTumor burdenDrug exposureTissue pharmacokineticsDrug levelsStem cell factorDiffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
Prager A, Martinez N, Beal K, Omuro A, Zhang Z, Young R. Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence. American Journal Of Neuroradiology 2015, 36: 877-885. PMID: 25593202, PMCID: PMC4731220, DOI: 10.3174/ajnr.a4218.Peer-Reviewed Original ResearchConceptsTreatment-related changesRecurrent tumorsHigh-grade gliomasSurgical resectionRecurrent high-grade gliomaLow relative cerebral blood volumeSubanalysis of patientsUtility of DWIRelative cerebral blood volumeTreatment-related effectsCerebral blood volumeWilcoxon rank sum testConventional MR imagingRank sum testConsecutive patientsHistopathologic evidenceMass lesionDSC perfusionRadiation therapyBlood volumeGrade gliomasPatientsLow perfusionTumorsDSC maps
2013
Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study.
Cloughesy T, Mischel P, Omuro A, Prados M, Wen P, Wu B, Rockich K, Xu Y, Lager J, Mellinghoff I. Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. Journal Of Clinical Oncology 2013, 31: 2012-2012. DOI: 10.1200/jco.2013.31.15_suppl.2012.Peer-Reviewed Original ResearchPan-PI3K inhibitorCohort 1Cohort 2Frozen tumor tissueTumor tissueTumor samplesK inhibitorsArchived tumor samplesPK/PD analysisPI3K/mTOR pathwayPD analysisTreatment of glioblastomaInhibition of proliferationPI3K inhibitorsPharmacodynamic impactEarly surgeryLast doseSurgical resectionCNS tumorsMean tumorRecurrent glioblastomaTumor resectionFFPE tumor samplesPK analysisCohort 3
2009
Patterns of care and outcomes in patients with intracranial hemangiopericytomas: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience
Dankwah-Quansah M, Gutin P, Bilsky M, Huse J, Rosenblum M, Abrey L, DeAngelis L, Omuro A. Patterns of care and outcomes in patients with intracranial hemangiopericytomas: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Journal Of Clinical Oncology 2009, 27: e13011-e13011. DOI: 10.1200/jco.2009.27.15_suppl.e13011.Peer-Reviewed Original ResearchIntracranial hemangiopericytomaStable diseaseDisease courseMemorial Sloan-Kettering Cancer Center experienceMedian progression-free survivalRare primary brain tumorsTargeted therapy eraMedian overall survivalProgression-free survivalCancer Center experienceOptimal clinical managementPatterns of carePrimary brain tumorsEfficacy of chemotherapyAdditional radiotherapyMedian KPSTherapy eraAdjuvant radiotherapySalvage treatmentCytotoxic chemotherapyOverall survivalSurgical resectionCenter experienceMedian ageRetrospective review